	US 11,896,604 B2
	Composition comprising HMSs/HMOs and use thereof
Bruce McConnell, La Tour de Peilz (CH); Emma Elison, Hjärup (SE); and Louise Kristine Vigsnæs, Copenhagen NV (DK)
Assigned to Glycom A/S, Hørsholm (DK)
Filed by Glycom A/S, Hørsholm (DK)
Filed on Jun. 21, 2021, as Appl. No. 17/353,730.
Application 17/353,730 is a continuation of application No. 15/903,959, filed on Feb. 23, 2018, granted, now 11,040,049.
Application 15/903,959 is a continuation in part of application No. 15/147,112, filed on May 5, 2016, abandoned.
Application 15/147,112 is a continuation in part of application No. 15/034,593, abandoned, previously published as PCT/DK2015/050332, filed on Oct. 29, 2015.
Claims priority of application No. PA201470663 (DK), filed on Oct. 29, 2014.
Prior Publication US 2021/0308159 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A61K 31/7016 (2006.01); A61P 1/12 (2006.01)

CPC A61K 31/702 (2013.01) [A61K 31/7016 (2013.01); A61P 1/12 (2018.01); A61K 2300/00 (2013.01)]

20 Claims

1. A method comprising:

selecting a non-infant human experiencing diarrhea-predominant irritable bowel syndrome (“IBS-D”);

selecting a daily dose comprising an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human; and

increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and improving stool consistency in the non-infant human by administering to the non-infant human the daily dose of from about 3 g to about 10 g of the one or more HMOs.